|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|USRE44186||ASTRAZENECA AB||Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method|| |
(a month ago)
|US6515117||ASTRAZENECA AB||C-aryl glucoside SGLT2 inhibitors and method|| |
(2 years from now)
|US7919598||ASTRAZENECA AB||Crystal structures of SGLT2 inhibitors and processes for preparing same|| |
(6 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8628799||ASTRAZENECA AB||Coated tablet formulation and method|| |
(1 year, 9 months from now)
|US8501698||ASTRAZENECA AB||Crystal structures of SGLT2 inhibitors and processes for preparing same|| |
(3 years from now)
|US8716251||ASTRAZENECA AB||Pharmaceutical formulations containing an SGLT2 inhibitor|| |
(4 years from now)
|US9616028||ASTRAZENECA AB||Bilayer tablet formulations|| |
(7 years from now)
Qternmet Xr is owned by Astrazeneca Ab.
Qternmet Xr contains Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride.
Qternmet Xr has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Qternmet Xr are:
Qternmet Xr was authorised for market use on 02 May, 2019.
Qternmet Xr is available in tablet, extended release;oral dosage forms.
Qternmet Xr can be used as treatment of type 2 diabetes mellitus.
The generics of Qternmet Xr are possible to be released after 12 November, 2030.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Product (NP)||May 2, 2022|
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic